Hancock Whitney Corp Has $3.05 Million Stock Holdings in Gilead Sciences, Inc. (NASDAQ:GILD)

Hancock Whitney Corp reduced its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 61.6% in the 2nd quarter, according to its most recent filing with the SEC. The firm owned 44,484 shares of the biopharmaceutical company’s stock after selling 71,495 shares during the period. Hancock Whitney Corp’s holdings in Gilead Sciences were worth $3,052,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently made changes to their positions in the company. Summit Trail Advisors LLC lifted its holdings in Gilead Sciences by 37.7% in the second quarter. Summit Trail Advisors LLC now owns 17,105 shares of the biopharmaceutical company’s stock valued at $1,174,000 after buying an additional 4,683 shares during the period. Thrivent Financial for Lutherans raised its position in shares of Gilead Sciences by 140.7% during the 2nd quarter. Thrivent Financial for Lutherans now owns 2,159,356 shares of the biopharmaceutical company’s stock valued at $148,153,000 after acquiring an additional 1,262,193 shares during the last quarter. Pacer Advisors Inc. lifted its stake in shares of Gilead Sciences by 24.7% in the 2nd quarter. Pacer Advisors Inc. now owns 7,889,663 shares of the biopharmaceutical company’s stock valued at $541,310,000 after purchasing an additional 1,564,792 shares during the period. AE Wealth Management LLC boosted its position in shares of Gilead Sciences by 11.7% in the 2nd quarter. AE Wealth Management LLC now owns 29,796 shares of the biopharmaceutical company’s stock worth $2,044,000 after purchasing an additional 3,124 shares during the last quarter. Finally, Sprucegrove Investment Management Ltd. grew its stake in shares of Gilead Sciences by 16.7% during the second quarter. Sprucegrove Investment Management Ltd. now owns 270,266 shares of the biopharmaceutical company’s stock worth $18,543,000 after purchasing an additional 38,700 shares during the period. Institutional investors own 83.67% of the company’s stock.

Wall Street Analysts Forecast Growth

GILD has been the topic of a number of recent analyst reports. Royal Bank of Canada raised their target price on Gilead Sciences from $72.00 to $74.00 and gave the stock a “sector perform” rating in a report on Wednesday, September 4th. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a research note on Thursday, August 15th. Raymond James raised shares of Gilead Sciences from a “market perform” rating to an “outperform” rating and set a $93.00 target price for the company in a research note on Monday, July 8th. Cantor Fitzgerald reissued a “neutral” rating and set a $70.00 price target on shares of Gilead Sciences in a research report on Monday, September 16th. Finally, Piper Sandler restated an “overweight” rating and issued a $95.00 price objective on shares of Gilead Sciences in a research report on Wednesday, September 11th. Twelve equities research analysts have rated the stock with a hold rating, seven have given a buy rating and two have given a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $82.06.

Gilead Sciences Trading Up 0.0 %

NASDAQ GILD opened at $83.94 on Friday. Gilead Sciences, Inc. has a 52 week low of $62.07 and a 52 week high of $87.86. The company has a debt-to-equity ratio of 1.18, a quick ratio of 0.95 and a current ratio of 1.14. The stock’s 50 day moving average price is $76.95 and its two-hundred day moving average price is $71.25. The stock has a market capitalization of $104.58 billion, a price-to-earnings ratio of 233.17, a PEG ratio of 2.80 and a beta of 0.18.

Gilead Sciences (NASDAQ:GILD) last posted its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.61 by $0.40. Gilead Sciences had a net margin of 3.79% and a return on equity of 29.34%. The company had revenue of $6.95 billion for the quarter, compared to the consensus estimate of $6.64 billion. As a group, analysts anticipate that Gilead Sciences, Inc. will post 3.78 earnings per share for the current fiscal year.

Gilead Sciences Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 27th. Stockholders of record on Friday, September 13th will be paid a dividend of $0.77 per share. The ex-dividend date is Friday, September 13th. This represents a $3.08 dividend on an annualized basis and a dividend yield of 3.67%. Gilead Sciences’s dividend payout ratio is 855.56%.

Insider Activity

In related news, insider Johanna Mercier sold 5,490 shares of the company’s stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $73.98, for a total transaction of $406,150.20. Following the sale, the insider now owns 114,979 shares in the company, valued at $8,506,146.42. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, insider Merdad Parsey sold 2,000 shares of Gilead Sciences stock in a transaction dated Monday, July 1st. The shares were sold at an average price of $68.63, for a total value of $137,260.00. Following the completion of the transaction, the insider now owns 96,380 shares of the company’s stock, valued at approximately $6,614,559.40. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, insider Johanna Mercier sold 5,490 shares of the company’s stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $73.98, for a total transaction of $406,150.20. Following the completion of the sale, the insider now directly owns 114,979 shares in the company, valued at $8,506,146.42. The disclosure for this sale can be found here. Insiders sold 36,847 shares of company stock worth $3,002,940 in the last quarter. Corporate insiders own 0.16% of the company’s stock.

Gilead Sciences Profile

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.